For decades, KRAS mutations in non-small cell lung cancer were considered nearly impossible to target with drugs. Krazati (adagrasib) has changed that outlook by offering a precision approach for patients with a specific KRAS G12C mutation. In this guide, you’ll learn what this medication is, how it works, and what clinical evidence supports its use.

What Is Krazati (Adagrasib)?

Krazati is the brand name for adagrasib, an oral medication that belongs to a class of drugs called KRAS inhibitors. It is designed for adults with non-small cell lung cancer that carries a specific mutation known as KRAS G12C. This mutation causes the KRAS protein to remain switched on, sending continuous signals for cancer cells to grow and divide. By targeting this protein directly, the Krazati drug offers a more precise treatment option than conventional chemotherapy. Before starting treatment, a biopsy or blood test must confirm the presence of the KRAS G12C mutation.

How Does Krazati Work in KRAS-Mutated Lung Cancer?

Adagrasib is a small molecule that binds to the mutant KRAS G12C protein and locks it in an inactive state. This prevents the protein from relaying growth signals, which can slow or stop tumor growth in some patients. Compared with traditional chemotherapy, this targeted approach aims to spare healthy cells and may lead to fewer systemic side effects. However, response varies from person to person. When considering this medication, your oncology team may evaluate:

  • Confirmation of a KRAS G12C mutation through biomarker testing
  • Disease progression after at least one prior systemic therapy
  • Your overall performance status and organ function
  • Potential drug interactions with other medications or supplements

Additionally, not every patient is eligible, and some may experience significant side effects. A thorough discussion with your oncologist can help determine if Krazati is appropriate for your situation.

FDA Approval and the KRYSTAL-1 Trial

Adagrasib FDA approval came in December 2022 for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. The approval was based on data from the KRYSTAL-1 trial, a phase 2 study that evaluated the drug in this specific patient population. In that trial, the overall response rate was around 43 percent, meaning tumors shrank in a meaningful proportion of participants. The median duration of response exceeded eight months among responders. According to the FDA, the medication received accelerated approval, and ongoing studies are evaluating long-term outcomes. Biomarker testing remains essential to identify eligible patients.

What to Expect and Practical Considerations

If you and your doctor decide that Krazati is appropriate, you will likely take it orally twice daily, with or without food. Your healthcare team will monitor you regularly through blood tests to check liver function, kidney function, and other health markers. Common side effects reported in clinical trials include diarrhea, nausea, fatigue, and elevated liver enzymes. Some patients might also experience heart rhythm changes or fluid retention. Fortunately, many side effects can be managed with supportive medications or dose adjustments. Because this therapy can interact with other drugs, you should tell your oncologist about all prescriptions, over-the-counter products, and supplements you use. Pregnant individuals should discuss contraception, as the drug may cause fetal harm. Consult a healthcare professional for personalized advice before making any treatment decisions.

Why Krazati Matters for KRAS-Mutated Lung Cancer

Krazati (adagrasib) represents a meaningful step forward for people with KRAS G12C-mutated non-small cell lung cancer, offering a targeted alternative after initial treatment. The KRYSTAL-1 trial and subsequent FDA approval underscore its potential to shrink tumors and extend time without progression for some patients. If you have advanced lung cancer, ask your oncology team about biomarker testing and whether this medication might fit your treatment plan. Learning more and having an informed discussion can help you make a confident decision.